<DOC>
	<DOCNO>NCT00732810</DOCNO>
	<brief_summary>To determine activity SCH 727965 participant breast cancer participant nonsmall-cell lung cancer ( NSCLC ) compare standard treatment . The standard treatment use capecitabine breast cancer erlotinib NSCLC . The study also determine activity SCH 727965 treatment participant experience cancer progression standard treatment .</brief_summary>
	<brief_title>SCH 727965 Patients With Advanced Breast Lung Cancers ( Study P04716 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age &gt; =18 year , either sex , race . Histologically cytologically confirm breast cancer NSCLC ; radiographic clinically advanced disease . BREAST CANCER : participant must previously receive taxane anthracycline ( unless anthracycline therapy contraindicate ) adjuvant and/or metastatic setting , participant HER2positive disease must progress trastuzumab concomitant subsequent lapatinib , participant must receive least one , two prior regimen recurrent metastatic disease ( endocrine biologic therapy count chemotherapeutic regimen ) . NSCLC : least one , two prior chemotherapeutic regimen advance disease . Measurable disease RECIST . Eastern Cooperative Oncology Group performance status 0 , 1 , 2 . Adequate hematologic , renal , hepatic organ function laboratory parameter . Ability swallow tablet . Known brain metastasis . For NSCLC , participant central nervous system metastasis eligible provide participant receive definitive local therapy ( ie , radiation therapy surgery ) , stop receive treatment corticosteroid , without symptom least 4 week randomization . History previous radiation therapy &gt; 25 % total bone marrow . Known HIV infection . Known active hepatitis B hepatitis C. Previous treatment SCH 727965 cyclindependentkinase inhibitor . BREAST CANCER : know dihydropyrimidine dehydrogenase deficiency , previous treatment capecitabine . NSCLC : previous treatment erlotinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>